Respiratorius (RESP) Q3 2025 earnings summary

Executive summary

• Significant progress made in advancing the VAL001 drug candidate, including a pre-IND meeting with the FDA confirming alignment with regulatory expectations for a phase III study targeting DLBCL.

• Strengthened financial position through a rights issue, raising over 10 MSEK to support continued development and licensing efforts for VAL001.

• No revenue generated; focus remains on R&D and securing a licensing agreement to achieve future cash flow positivity.

Financial highlights

• Net sales were 0 KSEK for both Q3 and the nine-month period, unchanged from the previous year.

• Result after financial items improved to -1,447 KSEK in Q3 (from -2,129 KSEK) and -5,258 KSEK for the nine months (from -5,699 KSEK) year-over-year.

• Earnings per share for Q3 were -0.18 SEK (vs. -0.42 SEK) and -0.67 SEK for the nine months (vs. -1.12 SEK).

• Cash and bank balances at period end were 8,802 KSEK, up from 3,129 KSEK at the start of the period.

Outlook and guidance

• The capital raised is expected to fund operations until a licensing deal for VAL001, which is anticipated to bring the company to cash flow positivity.

• Ongoing partner discussions and regulatory clarity position VAL001 for the next development phase.